Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Immunotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 30 results found since Jan 2013.
Ultrasound-Mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes
CONCLUSION: UMND enhanced PLGA-PEI NBs-STAT6 siRNA to repolarize TAMs from the M2 to the M1 phenotype, thus treating NSCLC. These findings provide a promising therapeutic approach for enhancing NSCLC immunotherapy.PMID:37491853 | DOI:10.2174/1567201820666230724151545
Source: Current Drug Delivery - July 26, 2023 Category: Drugs & Pharmacology Authors: Hong Shu Wenhao Lv Zhi-Jian Ren Hui Li Tiantian Dong Yao Zhang Fang Nie Source Type: research
Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses
Discussion: To our best knowledge, our study pioneered co-delivery system for hydrophilic siCD47 and hydrophobic R848. It can maximize break tumor immune escape caused by CD47 and simultaneously enhance antigen presentation by activating DCs for effector T cell killing while regulating the tumor microenvironment as expected. Not only does it conform to the reports of previous basic research, but also it can break the bottleneck of their clinical application hopefully. Collectively, our findings could lay the foundation for future therapeutic strategies of TNBC.
Source: Frontiers in Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Source Type: research
Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Biomed Pharmacother. 2023 Mar 22;161:114567. doi: 10.1016/j.biopha.2023.114567. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is a lack of optimal biomarkers for the prediction of response to this therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, termed zinc finger Asp-His-His-Cys-type palmitoyltransferases (ZDHHC), which precisely control vari...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 24, 2023 Category: Drugs & Pharmacology Authors: Zhiqing Lin Keke Huang Hui Guo Manli Jia Qiuqin Sun Xuhao Chen Jianmin Wu Qingqing Yao Peng Zhang Sergii Vakal Zhengzhi Zou Haiyao Gao Lei Ci Jiangfan Chen Wei Guo Source Type: research
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highligh...
Source: Frontiers in Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Source Type: research
Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer
Eur J Pharm Sci. 2023 Mar 21;185:106427. doi: 10.1016/j.ejps.2023.106427. Online ahead of print.ABSTRACTProstate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimula...
Source: European Journal of Pharmaceutical Sciences - March 22, 2023 Category: Drugs & Pharmacology Authors: Yao Sun Michael F Cronin Monique C P Mendon ça Jianfeng Guo Caitriona M O'Driscoll Source Type: research
Sialic Acid-Targeted Cyclodextrin-Based Nanoparticles Deliver CSF-1R siRNA and Reprogram Tumour-Associated Macrophages for Immunotherapy of Prostate Cancer
Eur J Pharm Sci. 2023 Mar 20:106427. doi: 10.1016/j.ejps.2023.106427. Online ahead of print.ABSTRACTProstate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimulating...
Source: European Journal of Pharmaceutical Sciences - March 22, 2023 Category: Drugs & Pharmacology Authors: Yao Sun Michael F Cronin Monique C P Mendon ça Jianfeng Guo Caitriona M O'Driscoll Source Type: research
Targeting the chemokine ligand 2-chemokine receptor 2 axis provides the possibility of immunotherapy in chronic pain
Eur J Pharmacol. 2023 Mar 10:175646. doi: 10.1016/j.ejphar.2023.175646. Online ahead of print.ABSTRACTChronic pain affects patients' physical and psychological health and quality of life, entailing a tremendous public health challenge. Currently, drugs for chronic pain are usually associated with a large number of side effects and poor efficacy. Chemokines in the neuroimmune interface combine with their receptors to regulate inflammation or mediate neuroinflammation in the peripheral and central nervous system. Targeting chemokines and their receptor-mediated neuroinflammation is an effective means to treat chronic pain. I...
Source: European Journal of Pharmacology - March 12, 2023 Category: Drugs & Pharmacology Authors: Shan Liu Xiao-Bing Lan Miao-Miao Tian Chun-Hao Zhu Lin Ma Jia-Mei Yang Juan Du Ping Zheng Jian-Qiang Yu Ning Liu Source Type: research
Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
Source: Pharmaceutical Research - December 7, 2022 Category: Drugs & Pharmacology Source Type: research
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy
Adv Drug Deliv Rev. 2022 Nov 23:114624. doi: 10.1016/j.addr.2022.114624. Online ahead of print.ABSTRACTThe development of carrier systems that are able to transport and release therapeutics to target cells is an emergent strategy to treat cancer; however, they following endocytosis are usually trapped in the endo/lysosomal compartments. The efficacy of drug conjugates and nanotherapeutics relies critically on their intracellular drug release ability, for which advanced systems responding to the unique lysosomal environment such as acidic pH and abundant enzymes (e.g. cathepsin B, sulfatase and β-glucuronidase) or equipped...
Source: Advanced Drug Delivery Reviews - November 26, 2022 Category: Drugs & Pharmacology Authors: Yinping Sun Yongjie Sha Guanhong Cui Fenghua Meng Zhiyuan Zhong Source Type: research
